

MedLife continues its acquisition and greenfield investment plans and announces the intention to sign a new syndicated loan of 40 million euros: "We also plan to invest in research, being the first Romanian private medical company to make research a strategic objective"

- *MedLife ended 2020 financial year with consolidated pro-forma sales of 251 million euros, becoming one of the largest private healthcare providers in the region*
- *The M&A program will remain a priority, MedLife having initiated 3-4 advanced discussions at national level and 1-2 at regional level*
- *The new contracted funds will be allocated to the development of the regional hospitals, by extending the existing units, to the infrastructure in the oncology area and to post covid programs*
- *The company will consolidate the efforts in the research area, and will invest 3-5 million in one of the most modern laboratories with a high biosecurity in virology, genetics and molecular biology in Romania.*
- *The figures budgeted for 2021 at consolidated level show 15% increase in sales, as well as a conservation of current profitability (EBITDA margin) at group level.*

Bucharest, March 26, 2021: MedLife Medical System, the leader of the private medical services market in Romania, announces the intention to increase its existing facilities by 40 million euros by signing a new syndicated loan; discussions are already underway with the banks. Depending on the opportunities, other own important liquidities will be added to this increase, if needed.

The syndicate of banks which would sign the new syndicated loan is comprising the following lenders: Banca Comercială Română, as coordinator, mandated lead arranger, documentation agent, facility & security agent and lender, BRD Groupe Société Générale, Banca Transilvania and Raiffeisen Bank as lead arrangers and lenders.

New funds will be dedicated to the consolidation and expansion of the group at national level, by developing medical units such as MedPark, where the patient would benefit from a full approach both in terms of the complexity of the medical act and the quality of related services. A major attention will be paid to the development of programs and projects in the pandemic context, projects related to prevention, oncology and medical radiotherapy, tech and digitization, the main objective being the needs of the patient in 2021, that was or not infected with COVID-19, who takes care of his health and who seeks to solve his medical needs in an efficient, quick and safe manner. Moreover, the company aims to continue the research activities, and to extend them through new investments.

"The research initiatives started since the beginning of last year, consistently and high conducted, have positioned MedLife as a regional pandemic watchdog, our team of specialists keeping informed in real time the authorities and the population about the SARS CoV 2 virus. These actions assured us an important role in society, assuming the moral responsibility to monitor the evolution of the pandemic. We have taken this role very seriously and that is why we aim to intensify our efforts in the research area. Regarding this, we have decided to invest between 3 and 5 million for the arrangement of a new biosafety III laboratory where we will work for the first time with live viruses. The land and part of the buildings have already been acquired, and the new unit being next to the group's central laboratory. The new laboratory will be part of MedPark and will become the most modern research genetics laboratory, virology and molecular biology in Romania" said Mihai Marcu, President and CEO of MedLife Group.

At the same time, the group's representatives announce that another targeted segment is the M&A program, both nationally and internationally, and the strengthening of country health infrastructure, where the patient can quickly access the medical services, from anywhere.

"We always believed that Romania has an extraordinary potential and exceptional people who know how to act in the crisis environment and who manage to face the challenges. The first pandemic year proved that a good and strategic mobilization helped us to move forward and that is why we want even more now to increase the medical infrastructure in our country, to create medical units that will serve serious and complex cases across the country, units that we will be able to easily compare with other large medical entities in Europe. The M&A program will also remain active, as we announced, we have three - four advanced negotiations in Romania and one - two outside. We make strategic plans, but we will also balance the investments depending on how the pandemic will evolve", said Mihai Marcu, President and CEO of MedLife Group.

In addition to national investment and development plans, MedLife will continue to strengthen its main business segments, clinics, corporate, hospitals, laboratories, pharma and dentistry, with the main strategy of adapting services to the current needs of patients and clients in the portfolio.

"2020 was a year in which we adapted a lot, prioritizing the needs of our patients. For example, in the area of clinics and laboratories we focused on screening programs for comorbidities or screening programs for those who went through Sars CoV2 infection, and in the area of hospitals we came to meet those with acute surgical emergencies. In the area of the corporate division, we had a similar policy, of adaptation. In this segment, we did not insist on the opportunistic increase in sales of services that could not be accessed in the short term by new clients, while risking to promote countercyclical economic policies which will be settled in the coming years. Instead, we focused on customized programs that support the critical need of companies to safely restart their business and protect their employees during the pandemic" said Mihai Marcu, President and CEO of MedLife Group.

MedLife Group ended 2020 with consolidated pro-forma sales at group level worth 251 million euros, increasing by 25.5% compared to the same period last year, being one of the largest players at regional level.

"But probably the biggest achievement of MedLife group in 2020 is the scientific, research activities and information of the population and the authorities on the evolution of strains from various countries, the seroprevalence acquired after the disease or as a result of vaccination, evolution of the pandemic in general. We will continue to be deeply engaged in this process in the years to come.

The coming months will be decisive for the evolution of the pandemic at European level but especially at national level. The number of vaccines administered will be directly correlated with the economic recovery and resumption of social life, inversely proportional to the number of people infected with SARS CoV 2. For the next period there are sufficient vaccines. The stakes will slowly shift to the vaccination capacity which should be increased as soon as possible to 100 thousand vaccines per day and gradually to 150 thousand. **But the central bet will be to convince the population to get vaccinated. After the vaccines will be administered for 5-7 million citizens of Romania, the hardship will begin. From the way we understand the dynamics of vaccination intention, up to 11-12 million vaccinated people will require a major effort to inform and promote the need for vaccination. The government and the business environment, the health authorities will have to unite their efforts, to start new educational actions, to patiently persuade each additional million people to be vaccinated. MedLife will soon begin a comprehensive study to measure this dynamic"** said Mihai Marcu, President and CEO of MedLife Group.

According to the company's representatives, the figures budgeted for 2021 at consolidated level show 15% increase in sales, as well as a maintenance of current profitability (EBITDA margin) at group level. The budgeted figures do not include the M&A transactions announced at the end of 2020, which will be added as the closing procedures are completed.

About MedLife Medical System:

MedLife Medical System started 26 years ago, has developed healthily and has become the largest provider of private medical services in Romania. Romanian entrepreneurs, who founded this company, invested and got involved to change the Romanian health system, believed in innovation and dared to aim as high as possible, to offer Romanian patients qualitative services, professionalism, care and respect for their needs.

The company operates the largest network of clinics, one of the largest networks of medical laboratories, general and specialized hospitals and has the largest corporate clients base for Health Prevention Packages in the country. It is also one of the largest private healthcare providers in Central and Eastern Europe in terms of sales.

MedLife Group has a history of success in terms of both organic growth and by acquisitions. Strong and experienced management team, composed 100% of Romanians, was able to create and manage these growth opportunities, gaining valuable knowledge and experience, which allows to find the best way to successfully continue the expansion.

Being a Romanian company with a tradition, MedLife chose to be listed on the Romanian Stock Exchange, being a model for listings on the local capital market. It has opened up new horizons, and through the corporate governance it has implemented, has inspired other local companies to embark on this path and help develop the Romanian capital and economy. The shares issued by MedLife SA are admitted to trading on the regulated spot market administered by the Bucharest Stock Exchange, Premium Category, with the trading symbol " M ".

During the pandemic, MedLife managed to play a key role in society and gain a detached leadership status in pandemic monitoring through active involvement in research activities.

The company continues to invest in projects in technology and infrastructure, with impact on the local community. It creates jobs and develops an ecosystem that contributes to the development and maintenance of a healthy Romania.